501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone: (604)
551-7831
Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix is
developing Marijuana Breathalyzer devices to give law enforcement
and employers a tool to enhance public safety
Vancouver, British Columbia --
November 7, 2022 -- InvestorsHub NewsWire -- Cannabix Technologies
Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix") developer of
marijuana breathalyzer devices for law enforcement and the
workplace reports that it has entered into a memorandum of
understanding with the Warren County, Pennsylvania, District
Attorney's office to pilot the Company's technology for detection
of ?9-tetrahydrocannabinol ("THC") and in human breath. The
Company's proprietary breath capture and laboratory-based marijuana
detection equipment (as described below) will be used to collect
and confirm THC in breath samples. Cannabix plans to supply 2
handheld Breath Collection Units (BCU) to Warren police before the
end of the year and such devices will be used in Warren County at
the discretion of its police force for up to 3 months or longer.
The Cannabix BCU can be used to collect time of
stop breath
samples immediately upon suspicion of cannabis use by a driver.
Field Samples collected using the BCU by Warren police (and Drug
Recognition Experts) will be processed at a designated laboratory
using proprietary "MS Breath Sampler" hardware.
Warren County
District Attorney Robert C. Greene, stated the following,
"marijuana use is here and has been for decades. Pennsylvania (PA) has legalized
the medical use of marijuana and recreational adult use is right
around the corner. Every state surrounding
Pennsylvania has legalized medical marijuana and more importantly,
Warren County borders the State of New York which has legalized
recreational use. The goal is to keep Warren County
citizens safe from impaired drivers.
Currently, in
Pennsylvania, an individual cannot drive if there is ANY marijuana
metabolite in their blood. Therefore, if an individual is
completely sober, but legally used marijuana in the weeks prior to
driving on PA roads, they are driving illegally according to PA law
and can be arrested and charged with Driving Under the Influence,
see 75 Pa.C.S.A.§3802(d)(1)(iii). And yes, this happens every day
in Pennsylvania.
We are excited about
the opportunity to work with Cannabix to assist in testing a breath
test device that can detect if an individual has smoked marijuana
in the past 2-3 hours. If this device is proven to be
reliable in PA Courts, this could be a game changer in keeping our
roads safer with new legislation and at the same time, not infringe
on citizens' rights who use marijuana legally and still want to be
able to drive a vehicle. Warren County looks forward to
working with Cannabix on the Pilot Program."
"Rav Mlait, CEO of Cannabix
stated, "Cannabix's collaboration with Warren County will help us
in our efforts to gather critical real-world data using our
technology and methods. The Warren County District Attorney's
office has an unwavering commitment to keeping its citizens safe as
laws surrounding marijuana consumption evolve and we commend their
leadership and participation in helping advance cutting-edge
cannabis breath technology. We are seeking additional collaborators
and welcome such interest."
Current forms of testing for marijuana use
can identify THC ranging from minutes to days after actual use,
making it impossible to show the difference between the two.
Studies¹ have shown that breath
is a better indicator of impairment than saliva, blood, or urine
because THC is present in breath for a relatively short period of
time (1-3 hours) after consumption; whereas, it is excreted at
detectable levels in other body fluids for many hours, days, or
even weeks after smoking. This short time period of detection in
breath aligns with the peak impairment window.
The Company's handheld Breath
Collection Unit ("BCU", Fig. 1) and newly developed laboratory "MS
Breath Sampler" (Fig. 2) are being used together to provide a new
method for drug detection that complements gold-standard mass
spectrometry (MS) and significantly simplifies laboratory analysis
methods, reduces sample turnaround times (thus minimizing operating
costs), while maintaining sensitive, precise results. It should be
noted the BCU is also being used in concert with the
Cannabix
FAIMS Detection Unit (a separate device, under
development, not part of this pilot, which is being developed as a
portable system capable of both breath collection and analyses in
the field).
The Cannabix BCU will provide
quick and nonintrusive breath sample collection and easy analysis
with no sample preparation needed in a lab setting using the
Company's "MS Breath Sampler" hardware. In comparison, existing and
legacy breath and saliva testing procedures require several sample
extraction and preparation steps prior to analysis, and analysis
itself can take from 1 - 3 hours per sample. This is expensive and
impractical. Also, existing and legacy breath and saliva testing
procedures tend to have inefficient, time-consuming collection
methods, and recoveries are still often poor. Cannabix has
developed unique approaches to breath testing that will reduce
costs and make operations and processes far more
efficient.
Readers should note, although the
Company has achieved proof of concept prototype for its BCU and MS
Breath Sampler, the testing method and device is still in the
preapproval stage and accordingly the Company is not currently
making any express or implied claims that the technology will
proceed to commercial use.
(1) Olla P, Ishraque
MT, Bartol S. 2020. Evaluation of Breath and Plasma
Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in
Medical Cannabis Patients. Cannabis and Cannabinoid Res.;
99-104.
Himes S. et al. 2013.
Cannabinoids in Exhaled Breath following Controlled Administration
of Smoked Cannabis. Clinical Chemistry; 1780–1789.
Beck O, Sandqvist S,
Dubbelboer I, Franck J. 2011. Detection of
delta9-tetrahydrocannabinol in exhaled breath collected from
cannabis users. J Anal Toxicol; 35:541– 4.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a
developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law enforcement
to identify recent marijuana use
that better aligns with impairment. Cannabix devices are in the
advanced prototype and pre-clinical testing stage.
We seek Safe Harbor.
On
behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information, contact
the Company at
info@cannabixtechnologies.com
The CSE has
not reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that its development of marijuana
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that existing "patent pending" technologies licensed by
the Company will receive patent status by regulatory authorities.
The Company is not currently selling commercial breathalyzers.
Actual results and future events could differ materially from those
anticipated in such information. These and all subsequent written
and oral forward-looking information are based on estimates and
opinions of management on the dates they are made and are expressly
qualified in their entirety by this notice. Except as required by
law, the Company does not intend to update these forward-looking
statements